AFP and hepatocellular carcinoma: Thirdly, we are considering longer cancer treatment courses and more aggressive neo-adjuvant therapies, to decrease elevated levels of the HCC biomarkers AFP and GGT, to determine if that permits subsequent transplantation with prolonged survival, especially in those patients with baseline AFP levels >1,000 IU/mL which can potentially be substantially decreased pre-transplant.